Alnylam's ALN-PCSsc shows durable LDL-C lowering

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said patients receiving ALN-PCSsc had a lowering of LDL-C that persisted for up to 140 days in an ongoing Phase I study. The therapy is a subcutaneous formulation of small interfering RNA (siRNA) against PCSK9.

The primary objective of the randomized, single-blind placebo-controlled study was to evaluate safety and tolerability of ALN-PCSsc in subjects with elevated baseline LDL-C. Secondary objectives included pharmacokinetics and activity assessment by PCSK9 and LDL-C levels. Alnylam presented the data at the European Society of Cardiology meeting. ...